Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001
Iovance Biotherapeutics received FDA clearance to proceed with its IND application for IOV-5001, a next-generation IL-12 tethered TIL therapy. The Phase 1/2 basket trial will begin enrolling patients in the second half of 2026, targeting advanced colorectal, triple-negative breast, and estrogen receptor-low breast cancers.
Key figures
- Drug Name
- IOV-5001
- Phase Of Trial
- Phase 1/2
- Historical response rate
- 63%
- Annual us deaths addressed
- 100,000+
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.